| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hayashi Y et al. | Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. | 1999 | Pacing Clin Electrophysiol | pmid:10234723 |
| Pilotto A et al. | The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233191 |
| Goddard AF et al. | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233187 |
| Gisbert JP | [Lansoprazole: a review of its role in Helicobacter pylori eradication therapy]. | 1999 | Rev Esp Enferm Dig | pmid:10231305 |
| Gisbert JP et al. | [Antral biopsy is sufficient to confirm Helicobacter pylori eradication with the "new" one-week long triple treatments]. | 1999 | Med Clin (Barc) | pmid:10227015 |
| Bergman KL et al. | Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. | 1999 | Antimicrob. Agents Chemother. | pmid:10223956 |
| Fish DN and Abraham E | Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients. | 1999 | Antimicrob. Agents Chemother. | pmid:10223952 |
| Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |
| Sato K and Tomioka H | Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells. | 1999 | J. Antimicrob. Chemother. | pmid:10223590 |
| Khan AA et al. | Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. | 1999 | Int. J. Antimicrob. Agents | pmid:10221415 |
| van der Hulst RW et al. | [Treatment of Helicobacter pylori infections]. | 1999 | Ned Tijdschr Geneeskd | pmid:10221109 |
| Abbott GW et al. | MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. | 1999 | Cell | pmid:10219239 |
| Hoffman JS et al. | Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215735 |
| Neville PM et al. | The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215734 |
| Lee JM et al. | Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215733 |
| Kashimura H et al. | Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215732 |
| Clifford K et al. | Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. | 1999 | Ann. Otol. Rhinol. Laryngol. | pmid:10214783 |
| Dubois J and St-Pierre C | In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. | 1999 | Diagn. Microbiol. Infect. Dis. | pmid:10212753 |
| McConnell SA and Amsden GW | Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. | 1999 | Pharmacotherapy | pmid:10212011 |
| Henry DC et al. | Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group. | 1999 | Clin Ther | pmid:10211537 |
| Miwa H et al. | Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. | 1999 | J. Gastroenterol. Hepatol. | pmid:10207779 |
| Zhou Q et al. | CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. | 1999 | Eur. J. Clin. Pharmacol. | pmid:10206083 |
| Laine L et al. | Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. | 1999 | Am. J. Gastroenterol. | pmid:10201465 |
| Smoot DT et al. | Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10201463 |
| Sonnenberg A et al. | The effect of antibiotic therapy on bleeding from duodenal ulcer. | 1999 | Am. J. Gastroenterol. | pmid:10201462 |
| Verbanck JJ et al. | Campylobacter jejuni II peritonitis in a CCPD patient: cure by oral clarithromycin. | 1999 Jan-Feb | Perit Dial Int | pmid:10201350 |
| Lee CK et al. | Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. | 1999 | Vaccine | pmid:10195786 |
| Rosário M et al. | [Profile of the resistance to macrolides and imidazoles of Helicobacter pylori in a sample of the Portuguese population]. | 1998 | Acta Med Port | pmid:10192979 |
| Gómez-Gil E et al. | Clarithromycin-induced acute psychoses in peptic ulcer disease. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10192720 |
| Fournier S et al. | Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10192709 |
| Gimenez Garcia R et al. | Fish tank granuloma: response to treatment with clarithromycin. | 1999 | J Eur Acad Dermatol Venereol | pmid:10188167 |
| Craig AM et al. | Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. | 1996 | Pharmacoeconomics | pmid:10160472 |
| Dempsey CL et al. | Drug usage evaluation: clarithromycin as sequential therapy. | 1993 | Hosp Formul | pmid:10130382 |
| Kohyama T et al. | Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. | 1999 | Antimicrob. Agents Chemother. | pmid:10103198 |
| Huang J and Hunt RH | Clarithromycin-based triple therapies. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102978 |
| Liu WZ et al. | Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102964 |
| Xiao SD et al. | High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102963 |
| Wong BC et al. | Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102962 |
| Van der Wouden EJ et al. | The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102961 |
| Zanten SJ et al. | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102960 |
| Graham DY et al. | Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102946 |
| Tirén U et al. | Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. | 1999 | Acta Paediatr. | pmid:10102149 |
| Navuluri R and Yue S | Understanding peptic ulcer disease pharmacotherapeutics. | 1999 | Nurse Pract | pmid:10100245 |
| Torgano G et al. | Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. | 1999 | Circulation | pmid:10096930 |
| Khoo KH et al. | Altered expression profile of the surface glycopeptidolipids in drug-resistant clinical isolates of Mycobacterium avium complex. | 1999 | J. Biol. Chem. | pmid:10092667 |
| Talley NJ et al. | Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. | 1999 | BMJ | pmid:10092259 |
| Sunazuka T et al. | Effects of erythromycin and its derivatives on interleukin-8 release by human bronchial epithelial cell line BEAS-2B cells. | 1999 | J. Antibiot. | pmid:10092202 |
| Ong EL | Prophylaxis against disseminated Mycobacterium avium complex in AIDS. | 1999 | J. Infect. | pmid:10090497 |
| Ramirez J et al. | Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. | 1999 | Clin Ther | pmid:10090428 |
| GarcÃa-Romero E et al. | [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. | 1999 | Gastroenterol Hepatol | pmid:10089703 |